Structure Therapeutics (GPCR) Insider Trading & Ownership $23.85 +1.13 (+4.97%) Closing price 04:00 PM EasternExtended Trading$23.56 -0.29 (-1.22%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends There is no recent insider trading on record for Structure Therapeutics, but the stock has been recently traded by U.S. Congress members, who may have more information about the industry than the general public. Get GPCR Insider Trade Alerts Want to know when executives and insiders are buying or selling Structure Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Structure Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellAverage Share PriceTotal Transaction10/4/2023Thomas R. CarperU.S. Congress Member (D-DE)Sell$54.57$1,001 - $15,000 (Data available from 1/1/2013 forward) GPCR Insider Trading Activity - Frequently Asked Questions What percentage of Structure Therapeutics stock is owned by insiders? 9.43% of Structure Therapeutics stock is owned by insiders. Learn more on GPCR's insider holdings. Structure Therapeutics Key ExecutivesDr. Raymond C. Stevens Ph.D. (Age 60)CEO & Director Compensation: $890.38kMr. Jun S. Yoon (Age 46)Co- Founder, CFO & Secretary Compensation: $627.64kDr. Mark A. Bach M.D. (Age 67)Ph.D., Chief Medical Officer Compensation: $672.06kDr. Yingli Ma Ph.D. (Age 50)Chief Technology Officer Compensation: $497.58kDr. Xichen Lin Ph.D. (Age 50)Chief Scientific Officer Mr. Tony PengSenior Vice President of LegalMr. Bob GatmaitanSenior Vice President of PeopleDr. Hui Lei Ph.D.Senior Vice President of ChemistryDr. Fang Zhang Ph.D.Executive VP & Head of BiologyMs. Lani IbarraSenior Vice President of Clinical Development Operations More Insider Trading Tools from MarketBeat Related Companies TG Therapeutics Insider Trades Cytokinetics Insider Trades Grifols Insider Trades Verona Pharma Insider Trades Krystal Biotech Insider Trades Ultragenyx Pharmaceutical Insider Trades Avidity Biosciences Insider Trades SpringWorks Therapeutics Insider Trades ADMA Biologics Insider Trades Organon & Co. Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:GPCR) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.